FDA Approved Thermo Fisher Scientific’s (TMO) Oncomine Dx Express Test

Thermo Fisher Scientific Inc. (NYSE:TMO) is one of the 10 Best Dip Stocks to Buy According to BillionairesOn July 3, Thermo Fisher Scientific Inc. (NYSE:TMO) announced receiving FDA approval for its Oncomine Dx Express Test on the Ion Torrent Genexus Dx Integrated Sequencer.

After the approval, this test is now authorized as an in vitro diagnostic and as a companion diagnostic for Dizal’s ZEGFROVY. ZEGFROVY is a targeted therapy for non-small cell lung cancer patients with EGFR exon 20 insertion mutations. The test is also approved for broader tumor profiling in solid tumors, detecting mutations across 46 genes with clinical or potential clinical significance.

FDA Approved Thermo Fisher Scientific's (TMO) Oncomine Dx Express Test

A workstation in a research lab stocked with laboratory products and services.

This is a significant achievement as it brings rapid next-generation sequencing closer to patients. The technology can deliver crucial genomic results in as little as 24 hours. This speed is important for cancer care, as delays in obtaining tumor profiles can prevent patients from receiving timely treatments.

Thermo Fisher Scientific Inc. (NYSE:TMO) is a healthcare company that is focused on accelerating research, solving complex analytical problems, boosting laboratory efficiency, and improving patient health.

While we acknowledge the potential of TMO as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you’re looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock.

READ NEXT: The Best and Worst Dow Stocks for the Next 12 Months and 10 Unstoppable Stocks That Could Double Your Money.

Disclosure: None.